Clinical trials: Digital Ulcer
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
n Ulcer, Scleroderma, Systemic
A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.
- Trial name
- NCT00725361
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Crohn Disease, Ulcerative Colitis
Digital Behavioral Interventions in Inflammatory Bowel Disease
Given the bidirectionality between psychological distress and disease activity in inflammatory bowel disease (IBD), whereby increased psychological distress exacerbates disease activity and vice versa, psychosocial aspects of IBD…
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases, Stress, Psychological
- Trial name
- NCT04861597
- Testing
- Internet based cognitive behavioral therapy, Digital mood tracking
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Digital Ulcers
Bosentan in Digital Ulcers
The aim of the study is to collect long-term efficacy, tolerability and safety data of bosentan in Systemic Sclerosis (SSc) patients suffering from ischemic digital ulcers (DUs).
- Trial name
- RAPIDS 2 OL (NCT00319696)
- Testing
- Bosentan 62.5 mg, Bosentan 125 mg
- Volunteers
- 116 people
- Sponsor
- Actelion
Systemic Sclerosis
Open-Label Study of Oral Treprostinil in Digital Ulcers
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects…
- Trial name
- DISTOL-EXT (NCT00848107)
- Testing
- treprostinil diethanolamine
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- United Therapeutics
Systemic Sclerosis, Scleroderma
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin.
- Trial name
- DISTOL-1 (NCT00775463)
- Testing
- treprostinil diethanolamine
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- United Therapeutics
Digital Ulcers
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
The DUAL-2 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration.
- Trial name
- DUAL-2 (NCT01474122)
- Testing
- Macitentan 3 mg, Macitentan 10 mg
- Volunteers
- 265 people
- Sponsor
- Actelion
Systemic Sclerosis, Ulcers
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
The DUAL-1 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration.
- Trial name
- DUAL-1 (NCT01474109)
- Testing
- macitentan 3mg, macitentan 10mg
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 289 people
- Sponsor
- Actelion